< 1 minute read
Sep. 17, 2021

“PROTAC 6”: IAP-based selective RIPK2 degrader

“PROTAC 6”

IAP-based selective RIPK2 degrader prolonged PD w/ 0.15 mpk SC Q3D dosing E3 binder switch and property-based opt. Commun. Biol., Mar. 20, 2020 GlaxoSmithKline, Stevenage, UK / PMCC

drughunter.com
Drug Hunter Team

“PROTAC 6” (GlaxoSmithKline (GSK) IAP-based selective RIPK2 degrader with prolonged in vivo PD)

Loading...

twitterlinkedinemail

Other molecules you may be interested in